不同方案治疗丙型肝炎合并艾滋病时的代谢指标对照观察  

The comparison of the therapeutic impacts on metabolism in hepatitis C virus and human immunodeficiency virus co-infected patients

作　　者：孙洪清[1] 黄琴[1] 沈芳[1] 邬敏[1] 周晓明[1] 蔡卫平[1] 胡芸文[1] 

机构地区：[1]复旦大学附属上海市公共卫生临床中心,200083

出　　处：《中华内分泌代谢杂志》2013年第4期311-313,共3页Chinese Journal of Endocrinology and Metabolism

基　　金：国家科技重大专项项目（2008ZX10001-008）;卫生部艾滋病防治研究项目（WA-2007-05）

摘　　要：探讨以蛋白酶抑制剂（protease inhibitors）或非核苷类反转录酶抑制剂（non-nucleoside reverse transcriptase inhibitors）为主方案治疗丙型肝炎病毒（HCV）/人类免疫缺陷病毒（HIV）合并感染患者对代谢的影响。采用随机、开放、对照方法收集初次就诊的273例HCV/HIV合并感染患者为研究对象。分别用蛋白酶抑制剂（PIs组）或非核苷类反转录酶抑制剂（NNRTIs组）为主的方案治疗。检查治疗前、后代谢指标。治疗后NNRTIs组与PIs组的甘油三酯分别为（1.93 ± 0.99）mmol/L和（1.62 ± 0.93）mmol/L，高密度脂蛋白胆固醇分别为（1.28 ± 0.55）mmol/L和（1.08 ± 0.53）mmol/L，低密度脂蛋白胆固醇分别为（2.60 ± 1.44）mmol/L和（2.22 ± 1.16）mmol/L，空腹血糖分别为（5.92 ± 1.21）mmol/L和（4.79 ± 0.47）mmol/L，血肌酐分别为（70.5 ± 14.6）μmol/L和（56.6 ± 8.3）μmol/L，血淀粉酶分别为（66.9 ± 27.5）U/L和（62.7 ± 33.8）U/L，2组比较为差异有统计学意义（均P〈0.01）。非核苷类反转录酶抑制剂为主治疗HCV/HIV合并感染的患者会加重代谢指标。To explore and compare the response of the protease inhibitors or non-nucleoside reverse transcriptase inhibitors-based therapeutic impact on metabolic indices in hepatitis C virus（HCV）/human immunodeficiency virus（HIV）co-infected patients. A randomized, open, and control approach was performed to enroll 273 cases of HCV/HIV co-infected patients on their initial visits and to choose protease inhibitors（PIs group）or non-nucleoside reverse transcriptase inhibitors（NNRTIs group）based therapy treatments for one year. Laboratory results of metabolic indices before and after the treatment were collected. After treatment, the levels of triglyceride in NNRTIs and PIs groups were（1.93 ± 0.99）mmol/L and（1.62 ± 0.93）mmol/L respectively, high density lipoprotein-cholesterol were（1.28 ± 0.55）mmol/L and（1.08 ± 0.53）mmol/L, low density lipoprotein-cholesterol were（2.60 ± 1.44）mmol/L and（2.22 ± 1.16）mmol/L, fasting plasma glucose were（5.92 ± 1.21）mmol/L and（4.79 ± 0.47）mmol/L, serum creatinine were（70.5 ± 14.6）μmol/L and（56.6 ± 8.3）μmol/L,and serum amylase were（66.9 ± 27.5）U/L and（62.7 ± 33.8）U/L respectively. The difference between the two groups was statistically significant（all P〈0.01）. There is a therapeutic impact on metabolic indices in patients wtih HCV / HIV co-infection after non-nucleoside reverse transcriptase inhibitors-based regimen.

关 键 词：比较 蛋白酶抑制剂 非核苷类反转录酶抑制剂 丙型肝炎病毒 人类免疫缺陷病毒合并 感染 

分 类 号：R512.91[医药卫生—内科学]